Skip to main content

Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica

In brief

Secukinumab raises 1-year remission to 41%, versus 20% with taper alone

In 381 patients with relapsed polymyalgia rheumatica, secukinumab plus a 24-week prednisone taper led to sustained remission at 52 weeks in about 41%, compared with 20% with the taper alone. Secukinumab also reduced cumulative steroid doses, but some infections and hypersensitivity reactions were more common, leaving safety with longer-term use an important question.

Journal
New England Journal of Medicine (Q1)
Published
3 June 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
John H Stone, Frank Buttgereit, Alain Saraux, Wolfgang A Schmidt, Christian Dejaco, Robert Spiera, et al.
PMID
42234540
DOI
10.1056/NEJMoa2602567

Why clinicians should know about it

  • Picked for Immunology and Allergy (top studies of the week, 22 November 2026): Phase 3 cytokine-targeted treatment trial in autoimmune disease

Abstract

BACKGROUND: Polymyalgia rheumatica is a common inflammatory disease characterized by pain and stiffness in the shoulders and hips. Glucocorticoids are the first-line treatment, but relapses and glucocorticoid-related toxic effects are common, which underscores the need for effective alternatives. Secukinumab is a fully human monoclonal antibody that selectively inhibits interleukin-17A. METHODS: We enrolled patients with recently relapsed polymyalgia rheumatica and randomly assigned them, in a 1:1:1 ratio, to receive secukinumab at a dose of 300 mg (SEC-300 group), secukinumab at a dose of 150 mg (SEC-150 group), or placebo for 52 weeks. Patients in all the groups also received prednisone on a tapering schedule for 24 weeks. The primary outcome was sustained remission at week 52, defined as remission (the absence of signs or symptoms attributable to polymyalgia rheumatica and no new diagnosis of giant-cell arteritis that warranted escape or rescue treatment) that was sustained from week 12 until week 52. The annual cumulative glucocorticoid dose was a secondary outcome. Safety was also assessed. RESULTS: A total of 381 patients underwent randomization, and 127 were assigned to each group. At 52 weeks, sustained remission was observed in 41.2% (95% confidence interval [CI], 32.8 to 49.7) of the patients in the SEC-300 group, in 40.6% (95% CI, 32.2 to 49.0) of those in the SEC-150 group, and in 20.4% (95% CI, 13.6 to 27.2) of those in the placebo group (P<0.001 for the comparison of each secukinumab dose with placebo). The mean adjusted annual cumulative glucocorticoid dose was 1603.7 mg in the SEC-300 group, 1683.2 mg in the SEC-150 group, and 2093.0 mg in the placebo group. Serious adverse events occurred in 13.5% of the patients in the SEC-300 group, in 15.9% in the SEC-150 group, and in 14.2% in the placebo group. Nasopharyngitis, hypersensitivity reactions, urinary tract infections, fungal infections, and back pain were more common in the secukinumab groups than in the placebo group. CONCLUSIONS: Among patients with relapsed polymyalgia rheumatica, treatment with secukinumab plus a 24-week glucocorticoid taper resulted in a higher percentage of patients with remission and in lower cumulative glucocorticoid doses than a glucocorticoid taper alone. (Funded by Novartis; REPLENISH ClinicalTrials.gov number, NCT05767034.).

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.